---
title: "BAM15"
canonical_url: https://peptidelibrary.app/library/bam15
description: "Mitochondrial protonophore uncoupler used in metabolic research to increase energy expenditure independently of beta-oxidation stimulation. Not FDA-approved; not a peptide."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# BAM15

BAM15 (also called N5,N6-bis(2-fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine) is a small molecule in the Mitochondrial Uncoupler (Protonophore) class. Increases inner-mitochondrial-membrane proton leak, uncoupling oxidative phosphorylation from ATP synthesis and raising energy expenditure in cells and rodents without the classic DNP-like off-target toxicity profile in published models.

Mitochondrial protonophore uncoupler used in metabolic research to increase energy expenditure independently of beta-oxidation stimulation. Not FDA-approved; not a peptide.

Also known as: N5,N6-bis(2-fluorophenyl)[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine.

Categories: Fat Loss, GLP-1/Metabolic, Experimental.

## Classification

- Type: Mitochondrial uncoupler / small molecule
- Mechanism class: Mitochondrial Uncoupler (Protonophore)
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Increases inner-mitochondrial-membrane proton leak, uncoupling oxidative phosphorylation from ATP synthesis and raising energy expenditure in cells and rodents without the classic DNP-like off-target toxicity profile in published models.

Targets: Mitochondrial inner membrane.

Origin: Synthetic oxadiazolopyrazine small molecule.

## Properties

- Sequence: N/A (small-molecule mitochondrial protonophore; not a peptide)
- Molecular formula: C16H10F2N6O
- Molecular weight: 340.29 g/mol
- CAS number: 210302-17-3
- Half-life: Not established (limited public PK; primarily preclinical/in vitro characterization)

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: Lab & animal studies
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 3
- Latest source: 2022

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice. Nat Commun. 2020. 2020. Preclinical: animal or lab study. Population: Mice on a diet that causes obesity. More nutrient oxidation and less body fat without a change in food intake, lean mass or body temperature, plus better insulin sensitivity in clamp studies. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/32409697/)
2. Mitochondrial uncoupling attenuates sarcopenic obesity by enhancing skeletal muscle mitophagy and quality control. J Cachexia Sarcopenia Muscle. 2022. 2022. Preclinical: animal or lab study. Population: Mice with obesity-related muscle loss. Lower body weight, more muscle mass and grip strength, and activation of mitochondrial quality-control pathways. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/35304976/)
3. Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Mol Metab. 2014. 2014. Preclinical: in vitro (cells or tissue). Population: Cultured cells; mice with acute kidney ischaemia-reperfusion injury. Raised the maximum rate of mitochondrial respiration with less cell toxicity than the older uncoupler FCCP, and protected mice from kidney injury. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/24634817/)

## Safety

Side effects: Hyperthermia risk class-effect of uncouplers; No approved human dose.

Risks: Uncouplers can be dangerous if misused; Research-only.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

BAM15 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is BAM15?

Mitochondrial protonophore uncoupler used in metabolic research to increase energy expenditure independently of beta-oxidation stimulation. Not FDA-approved; not a peptide.

### How does BAM15 work?

Increases inner-mitochondrial-membrane proton leak, uncoupling oxidative phosphorylation from ATP synthesis and raising energy expenditure in cells and rodents without the classic DNP-like off-target toxicity profile in published models.

### Is BAM15 FDA approved?

No. BAM15 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of BAM15?

Reported half-life for BAM15 is Not established (limited public PK; primarily preclinical/in vitro characterization). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of BAM15?

BAM15 has the sequence N/A (small-molecule mitochondrial protonophore; not a peptide), giving a chain of 2 amino acids. Its molecular formula is C16H10F2N6O.

### What peptides are similar to BAM15?

Compounds most often compared with BAM15 include 5-Amino-1MQ, SLU-PP-332, AICAR and Tesofensine. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [PubChem BAM15](https://pubchem.ncbi.nlm.nih.gov/compound/BAM15)
- [Targeting Mitochondrial Dysfunction to Prevent Endothelial Dysfunction and Atherosclerosis in Diabetes: Focus on the Novel Uncoupler BAM15 — Int J Mol Sci, 2025](https://pubmed.ncbi.nlm.nih.gov/40429748/)
- [BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases — Front Endocrinol (Lausanne), 2023](https://pubmed.ncbi.nlm.nih.gov/37900126/)
- [BAM15 improves oocyte quality against obesity via PPARγ-dependent mitochondrial function — Protein Cell, 2026](https://pubmed.ncbi.nlm.nih.gov/42178393/)
- [BAM15 inhibits endothelial pyroptosis via the NLRP3/ASC/caspase-1 pathway to alleviate atherosclerosis — Atherosclerosis, 2025](https://pubmed.ncbi.nlm.nih.gov/40393254/)
- [Beneficial effects of MGL-3196 and BAM15 combination in a mouse model of fatty liver disease — Acta Physiol (Oxf), 2024](https://pubmed.ncbi.nlm.nih.gov/39152636/)
